Multiple Sclerosis
Tysabri Recommended By Nice for Use In Highly Active Relapsing Remitting Multiple Sclerosis In the Final Appraisal Determination
Published in Healthcare Finance, Tax and Law Weekly, July 18th, 2007
"This decision offers people with highly active relapsing remitting multiple sclerosis hope of regaining control of their disease," commented Professor Gavin Giovannoni, The Royal London Hospital. "TYSABRI represents a significant advance in MS treatment, offering real...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals Appoints Pharmaceutical and Medical Device Veteran to Board of Directors - Aging
Budget Impasse Requires PA Department of Aging to Furlough Half of its Workforce - Aging
Ed Koch, Bob Weiner Urge Home Care Alternatives to Nursing Homes; Seek Congress Address 'Silent Sadness of Seniors' Forced Unnecessarily to Leave Own Homes - Allscripts
Troy Moritz Joins Allscripts as Chief Security Officer - Alzheimer Disease
Scientists at Chang-Gung University publish new data on Alzheimer disease - Angiology
Judge Grants Diomed Permanent Injunction in '777 Patent Case - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
